Literature DB >> 10379705

Acquired skin disease of hemidesmosomes.

D Zillikens1.   

Abstract

The hemidesmosome is a membrane-associated supramolecular dermal epidermal complex linking the cytoskeleton of the basal keratinocyte to structures within the papillary dermis. Different components of this complex have been identified as autoantigens in autoimmune bullous skin diseases. Some of the autoantigens have been characterized at the molecular level. Little is known, however, about the factors that initiate the production of autoantibodies. By histopathology, acquired skin diseases of hemidesmosomes show subepidermal blisters and by direct immunofluorescence, linear deposits of IgG, C3 or IgA at the dermal epidermal junction. Bullous pemphigoid (BP) is the most common acquired disease of hemidesmosomes. Two proteins, BP180 and BP230, have been identified as primary targets of autoantibodies in BP. In addition, pemphigoid/herpes gestationis, lichen planus pemphigoides, cicatricial pemphigoid and linear IgA disease are characterized by an immune response to BP180. Laminin 5 is another well-characterized anchoring filament-lamina densa component of hemidesmosomes. Patients with autoantibodies to laminin 5 show the clinical phenotype of cicatricial pemphigoid. Other acquired skin diseases of the hemidesmosomes reveal autoantibodies to a plectin-like protein, the beta4 subunit of alpha6beta4 integrin, uncein and a not yet characterized 168 kDa protein. Recently, diseases with autoantibodies to 105 and 200 kDa proteins of the lower lamina lucida have been reported. The association of these autoantigens with hemidesmosomes still needs to be demonstrated. Finally, anchoring fibrils associate with the dermal epidermal anchoring complex. The major structural component of anchoring fibrils is type VII collagen, the autoantigen of epidermolysis bullosa acquisita.

Entities:  

Mesh:

Year:  1999        PMID: 10379705     DOI: 10.1016/s0923-1811(99)00019-5

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  8 in total

1.  The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.

Authors:  E Schmidt; S Reimer; N Kruse; E B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Oral lichenoid lesions: distinguishing the benign from the deadly.

Authors:  Susan Müller
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

3.  Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa.

Authors:  G T Higgins; R B Allan; R Hall; E A Field; S B Kaye
Journal:  Br J Ophthalmol       Date:  2006-04-13       Impact factor: 4.638

4.  Evaluation of recombinant antigen-based assays for diagnosis of bullous autoimmune diseases.

Authors:  G D'Agosto; A Latini; M Carducci; A Mastroianni; A Vento; P Cordiali Fei
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

5.  14-3-3 sigma isoform interacts with the cytoplasmic domain of the transmembrane BP180 in keratinocytes.

Authors:  Yunyuan Li; Xiaoyue Lin; Ruhangiz T Kilani; Jonathan C R Jones; Aziz Ghahary
Journal:  J Cell Physiol       Date:  2007-09       Impact factor: 6.384

6.  Targeted proteolysis of plectin isoform 1a accounts for hemidesmosome dysfunction in mice mimicking the dominant skin blistering disease EBS-Ogna.

Authors:  Gernot Walko; Nevena Vukasinovic; Karin Gross; Irmgard Fischer; Sabrina Sibitz; Peter Fuchs; Siegfried Reipert; Ute Jungwirth; Walter Berger; Ulrich Salzer; Oliviero Carugo; Maria J Castañón; Gerhard Wiche
Journal:  PLoS Genet       Date:  2011-12-01       Impact factor: 5.917

Review 7.  The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases.

Authors:  Cassian Sitaru; Sidonia Mihai; Detlef Zillikens
Journal:  Arch Dermatol Res       Date:  2007-02-03       Impact factor: 3.017

8.  Vulvar lichen planus pemphigoides.

Authors:  J Loyal; S Rashtak
Journal:  Int J Womens Dermatol       Date:  2017-08-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.